Form 4: Enliven Therapeutics' Chief Scientific Officer Sells Shares Under 10b5-1 Trading Plan

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, sold 12,000 shares of common stock on July 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 1, 2024, Joseph P. Lyssikatos, the Chief Scientific Officer of Enliven Therapeutics, sold 12,000 shares of the company's common stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on June 26, 2023.
• The shares were sold at a weighted average price of $22.8947, with individual trades ranging from $22.6459 to $23.635.
• Following the transaction, Lyssikatos directly owns no shares but indirectly owns 1,105,035 shares through The Lyssikatos Revocable Trust 12/15/2011, for which he serves as trustee.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't inherently indicate a positive or negative outlook.

Industry Context

Sales by company insiders are a common occurrence, and the use of 10b5-1 trading plans allows insiders to sell shares over a period of time while avoiding concerns about trading on non-public information. It is important to note that the sale does not necessarily indicate a negative outlook on the company's future prospects.

Stakeholder Impact

• The sale of shares by a company officer could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates